Tags: Drug.
DOV 216303 is an antidepressant drug originally developed by DOV Pharmaceutical and now licensed to the larger pharmaceutical company Merck & Co. which is currently in clinical trials. It is a so-called triple reuptake inhibitor (TRI) or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is expected to launch sometime around 2011. It is the racemic mixture of DOV 21947 and its (–)-enantiomer. Its IC50 values for SERT NET and DAT are Ki 14 nM 20 nM and 78 nM respectively.
